Novel Parkinson´s Disease therapy targeting iron-related cell death and alpha synuclein aggregation
| Reference number | |
| Coordinator | Pronexus Analytical AB |
| Funding from Vinnova | SEK 2 952 936 |
| Project duration | October 2020 - October 2024 |
| Status | Completed |
| Venture | Eurostars |
Important results from the project
We have developed the LC-MS/MS method for quantification of SP-420 and its iron chelate Fe(SP-420)2. We evaluated the kinetics and the distribution of SP-420 and Fe(SP-420)2 in plasma, CSF, body organs and brain. Only about 1% of plasma SP-420 could pass into the brain. However, SP-420 still could recruit the Fe3+ ions and clear the complex into the CSF. The results demonstrate that SP-420 showed a high bioavailability and iron chelating properties in blood but limited brain delivery in vivo.
Expected long term effects
The results of the study indicate that SP-420 possesses high iron chelating properties in blood and therefore, it could be efficient in treatment of diseases related to the iron overload. The project coordinator Pharmacosmos has initiated a phase II clinical trial in transfusion-dependent thalassemia.
Approach and implementation
Pronexus achieved the goals and tasks specified in the WP3: TASK 3.1 We implemented the data from the earlier experiments to design the in vivo studies. TASK 3.2 We measured the PK profiles of SP-420 and its iron complex by LC-MS/MS in rat plasma and CSF samples. TASK 3.4 We measured the targeted bioavailability of SP-420 in the brain and in the CSF. TASK 3.5 We evaluated partial dissociation of the iron SP-420 complex in blood. TASK 3.6 We selected SP-420 as the most suitable candidate.